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ABSTRACT 
 
Protein-protein interactions are required for many viral and cellular functions and are potential targets for novel 
therapies. Here we detail a series of genetic and biochemical techniques used in combination to find an essential 
molecular contact point on the duck hepatitis B virus polymerase. These techniques include differential 
immunoprecipitation, mutagenesis and peptide competition. The strength of these techniques is their ability to identify 
contact points on intact proteins or protein complexes employing functional assays. This approach can be used to aid 
identification of putative binding sites on proteins and protein complexes which are resistant to characterization by 
other methods.  
 
 
 
INTRODUCTION 
 
Protein-protein interactions are essential for most cellular 
processes. Not surprisingly, many human diseases can 
be linked to abnormal protein contacts, including some 
forms of leukemia and neurodegenerative disease (1). 
Additionally, protein-protein interactions provide 
therapeutic targets in the treatment of cancer and 
infectious diseases (2), and development of small 
molecule inhibitors of protein-protein interactions is a 
burgeoning field of research. 
 
Several techniques exist to examine protein-protein 
interactions. Yeast two-hybrid systems [reviewed in (3)] 
involve fusing proteins to either the DNA binding or 
transcriptional activation domains of the Gal4 
transcription factor. If binding occurs in yeast, a reporter 
gene is expressed. Glutathione-S-transferase (GST) 
pulldown is also used to test protein interactions (4). This 
technique entails expressing GST fusion proteins, 
allowing them to bind the target protein and purifying 
the complex by GST-glutathione affinity purification. 
Similar techniques include co-immunoprecipitation with 
or without chemical crosslinking. Peptide phage display 
[reviewed in (5)] involves displaying a library of foreign 
peptides on the end of coat proteins on the surface of 
bacteriophage particles. The library is then screened by 
affinity selection against an immobilized binding 
partner, and through several rounds peptides with high 
affinity for the target can be identified. Limitations of 
these techniques are that they are primarily appropriate 
for detection of inter-molecular binding and that a 
positive result indicates these proteins or protein 
fragments can interact under the conditions of the assay, 
not that they necessarily do interact under physiological 
conditions. Specifically, intra-molecular interactions and 
interactions involving proteins that require numerous 
cofactors or chaperones to fold properly are difficult or 
impossible to analyze by these methods.      
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One protein that has been extremely difficult to study is 
the duck hepatitis B virus (DHBV) polymerase (P). 
DHBV is a common model for the human pathogen 
hepatitis B virus (HBV). HBV chronically infects more 
than 350 million people worldwide and is the leading 
cause of hepatocellular carcinoma (6). These DNA 
viruses replicate by reverse transcription of an RNA 
intermediate in which DNA synthesis is primed by P 
itself, resulting in covalent attachment of the product 
DNA to P. This feature can be exploited in a priming 
assay, which measures covalent attachment of 
radiolabeled dGMP to P. Several chaperones are needed 
for proper folding and function of P, including HSP 90, 
HSP 70, HSP 40 and Hop (7, 8). The requirement of 
template RNA and cellular chaperone cofactors for P to 
become functional has made studying the structure of P 
using standard techniques very difficult and has 
prevented characterization of P by X-ray crystallography. 
Therefore, new techniques are needed to understand the 
folding of P and to identify inter- or intra-molecular 
contact sites involving P. 
   
Here we describe a series of biochemical and genetic 
techniques that we employed to identify an essential 
molecular contact site on P. Our results and their 
implications have been published (9). These data will be 
shown as examples. These approaches can be used to 
identify putative binding sites within protein complexes 
resistant to standard approaches. The summary of how 
we applied this general approach to assess DHBV P is in 
Table 1. 
 
Table 1: Analytical strategy for binding site 
identification. 
Step  General Approach  DHVB P 
1  Develop a collection of 
sequence-specific 
binding agents 
Developed a panel of monoclonal 
antibodies to the amino-terminal 
domain of P 
2 Assess  differential 
exposure of epitopes 
for binding agents in 
Step 1 
Immunoprecipitate in low vs. high 
detergent buffer 
3 Identify  putative 
binding sites by 
location of epitopes 
and sequence analysis 
Identified conserved region aa 
177-183 based on homology 
alignment and position of epitopes 
that are differentially exposed 
4 Mutate  conserved 
residues within 
putative binding site 
Mutated residues within aa 177-
183 
5 Test  mutants  in 
functional assays 
Assessed mutants in DNA 
priming and partial proteolysis 
6 Compete  interaction 
with peptides 
containing putative 
binding site 
Dose dependent decrease in 
priming when peptide containing 
aa 177-183 was added 
MATERIALS AND METHODS 
 
Materials 
 
Monoclonal antibodies were generated against COOH-
His tagged terminal protein domain of DHBV P (10). In 
vitro transcription was performed using the T7 or T3 
Megascript kits (Ambion) according to manufacturer’s 
instructions.  In vitro translation of P was performed 
using rabbit reticulocyte lysate (Promega) with 35S-
Methionine (Amersham). Peptides were custom 
synthesized (Genscript). 
 
Differential immunoprecipitation (Protocol 1) 
 
Protein A/G beads (Calbiochem) were suspended in 
either RIPA (20 mM Tris pH 7.2,150 mM NaCl, 1% Triton 
X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate [SDS]) or IPP150 (10 mM Tris pH 7.5, 150 mM 
NaCl, 0.1% NP40) along with bovine serum albumin (0.1 
ug/ul). Excess monoclonal antibodies were added to 
protein A/G beads and rocked at 4°. Antibody-bead 
complexes were washed and then incubated overnight 
with  in vitro translated P in either RIPA or IPP150. 
Immunocomplexes were collected and washed with 
RIPA or IPP150. P was released by boiling in Laemmli 
Buffer. Samples were resolved by SDS-polyacylamide gel 
electrophoresis [SDS-PAGE] and exposed to either 
autoradiography film or a phosphorimager screen. 
 
Bioinformatics 
 
To find putative binding sites we obtained protein 
sequences of P for eight different hepadnaviruses from 
the National Center for Biotechnology Information 
(NCBI) Entrez Protein website 
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Prot
ein]. The overall sequence identity between these viruses 
is 26%. We aligned the sequences using Clustal W. 
Motifs of 4-10 amino acids with >80% homology were 
considered putative binding sites and were investigated 
further. 
 
DNA priming assay  
 
P was translated in vitro in the presence of ε, the RNA 
required for activation of P (11, 12) and to initiate DNA 
synthesis (13, 14). 1 µl of a 1:1 mixture of 48 mM MgCl2 
and [α-32P]dGTP was added, and the reaction was 
incubated at 37° for 30 minutes. The reaction was     
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stopped by addition of Laemmli Buffer, and P was 
resolved by SDS-PAGE.  
 
Detection and quantitation of normalized priming 
signal 
 
An aliquot of the in vitro translation was removed prior 
to the priming reaction and resolved by SDS-PAGE to 
monitor translation efficiency. Because [α-32P]dGMP 
became covalently attached to a 35S-labeled protein in the 
priming reaction, we blocked the 35S signal by covering 
the dried gel with a piece of exposed autoradiography 
film, effectively impeding the 35S signal while not 
inhibiting the 32P signal. Both 35S translation and 32P 
priming signals from the phosphorimager were analyzed 
using ImageQuant software (Molecular Dynamics). The 
priming signal was divided by its cognate translation 
signal to normalize for translation efficiency. 
 
Partial proteolysis (Protocol 2) 
 
P was translated in vitro. Diluted papain (Sigma) was 
added to a total volume of 20 ul and the mixture was 
incubated at 14° for 10 minutes (12). Digestion was 
stopped by rapidly placing the samples in an ice water 
slurry followed by addition of 20 ul 2.5X Laemmli 
sample buffer and boiling for 4 minutes. Digested P was 
resolved by SDS-PAGE. Gels were dried and P was 
detected by phosphorimage analysis. 
 
Monoclonal antibody inhibition of priming 
 
Monoclonal antibodies were purified by protein A 
affinity chromatography. These mAbs were added 
following in vitro translation of P and allowed to bind to 
their epitopes. ε, MgCl2 and [α-32P]dGTP were then 
added to permit priming (9). The priming signal was 
normalized to translation efficiency as described above. 
 
Peptide competition (Protocol 3) 
 
Peptides containing the T3 motif and irrelevant peptides 
were synthesized and suspended in 100% dimethyl 
sulfoxide (DMSO) (Sigma) at 100 mM. The peptides were 
then diluted to 10 mM in 10% DMSO with water. The 
final concentration of DMSO in all reactions was 1%. P 
was translated in vitro in the presence of ε and peptide 
(0.25-1.0 mM), and then MgCl2 and [α-32P]dGTP were 
added to initiate priming (9). The samples were resolved 
by SDS-PAGE, the gels were dried and P was detected by 
phosphorimage analysis. Priming signal was normalized 
to translation efficiency. 
RESULTS 
 
Identification of systems amenable to this approach 
 
Conditions under which these approaches would be 
useful include: 
•  Protein-protein interactions that are resistant to 
characterization using standard GST fusion or yeast 2-
hybrid analyses; 
•  A  s o u r c e  o f  m o n o c l o n a l  a n t i b o d i e s  ( m A b s )  o r  
similar specific binding agents must be available. If 
mAbs cannot be made, single chain fragment variable 
reagents from phage display libraries could be used (15); 
•  Analytical quantities of functional protein, 
obtained by purification from bacteria, in vitro 
translation, baculovirus infection of insect cells or other 
methods; and 
•  A functional assay for protein activity. 
 
Differential immunoprecipitation 
 
Differential immunoprecipitation involves using 
antibodies or other sequence specific reagents to 
precipitate a protein under different buffer conditions. 
We used varying detergent concentrations, high and low, 
along with six monoclonal antibodies to determine 
structural changes and the existence of putative contact 
sites on the DHBV polymerase. In order for this method 
to be useful, several conditions must be met. First, the 
antibodies or other sequence-specific binding reagents 
must recognize one or more motifs on the protein. Also, 
at least one of the antibodies needs to recognize its 
epitope and immunoprecipitate (IP) the protein in the 
high detergent conditions. In our case we used RIPA, a 
partially denaturing buffer that breaks most weak 
protein-protein contacts but does not completely 
denature most proteins. Under less stringent buffer 
conditions that retain more protein-protein contacts, one 
o r  m o r e  o f  t h e  a n t i b o d i e s  m u s t  n o w  b e  u n a b l e  t o  
recognize their target. We chose IPP150 as the low 
stringency buffer because P retains sequence-specific 
RNA binding activity in this buffer (16). If these 
conditions are met, it can be concluded that detergent 
treatment can cause conformational changes in the 
protein and binding sites may be present on the protein. 
If a binding site is causing the differential 
immunoprecipitation, occupancy of the binding site in 
the mild conditions would occlude the antibody epitopes 
(Fig. 1). Figure 2 shows an example of differential IP 
using a panel of mAbs and two different buffers. In the 
high detergent buffer (RIPA) all of the mAbs recognize 
their epitopes, while in IPP150 buffer, which has less     
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detergent and retains many protein contacts, only mAbs 
9, 11 and 12 recognize their epitopes. 
 
 
Fig. 1: Summary of how differential exposure of mAb epitopes can lead to 
identification of protein-protein contacts. (A) Under normal conditions only 
some of the antibodies can bind their epitopes due to occlusion of the 
epitopes by the ligand bound to the contact site. (B) Treatment with 
partially denaturing buffer dissociates the protein contact site, exposing 
the monoclonal antibody epitopes. Mutagenesis (C) and peptide 
competition (D) at the contact site can both disrupt binding of the ligand 
for the motif and expose the epitopes in a pattern similar to that induced 
by the partially denaturing buffer. 
 
 
Fig. 2: Differential immunoprecipitation using high and low detergent 
buffers.  An example of differential immunoprecipitation in RIPA and 
IPP150 buffers. Unprecipitated in vitro translation sample and 
immunoprecipitation with a polyclonal antibody are controls. Note that 
mAbs 5, 6 and 10 immunoprecipitate P only under partially denaturing 
conditions. This figure was originally published in (9). 
Identification of putative contact sites and 
mutagenesis 
 
If differential precipitation has been observed with a 
sequence-specific reagent, the epitopes the reagent 
recognizes should be mapped. Once a region of the 
protein has been implicated by epitope mapping, genetic 
alignment and mutagenesis can help identify putative 
contact sites. First, to find potential contact sites, align 
multiple related protein sequences and look for regions 
of high homology. An example of a sequence homology 
alignment using eight different hepadnaviruses is shown 
in Figure 3. Groups of proteins with very high homology 
overall will not be amenable to this analysis because 
there will be too many regions that are similar. Other 
genetic features that can aid in identification of potential 
binding sites include hydrophilicity and secondary 
structure analyses to identify amino acids that may be 
exposed on the surface of the protein.  
 
 
Fig. 3: Sequence homology aligment of multiple hepadnaviruses. P 
sequences from eight hepadnaviruses were aligned. Sequences with a 
>80% homology are shaded green. The T3 motif is indicated. DHBV, Duck 
hepatitis B virus, SHBV, Stork hepatitis B virus, HHBV, Heron hepatitis B 
virus, RGHBV, Ross’ goose hepatitis B virus, WHV, Woodchuck hepatitis 
virus, GSHV, Ground squirrel hepatitis virus, WMHBV, Wooly monkey 
hepatitis B virus, HBV, Hepatitis B virus. Modified from a figure originally 
published in (9). 
 
Mutagenesis can be used to test if an implicated region is 
a potential contact site and to determine specific residues 
involved in binding. If the target residues within the 
putative contact site are essential for the interaction, their 
disruption will expose mAb epitopes normally obscured 
in low detergent buffer, similar to treatment with 
partially denaturing buffer (Fig. 1). Figure 4 shows how 
mutations can expose antibody epitopes that are 
normally obscured.     
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Fig. 4: Mutations can expose epitopes that are normally obscured. P with 
a mutation that did not affect binding at the contact site (Y181F) or with 
mutations that did disrupt binding (I179D/L180D) were 
immunoprecipitated with the indicated antibodies in IPP150 buffer. The 
epitopes for mAbs 5, 6 and 10 were exposed both by mutations at the 
contact site and high detergent (compare Figs. 2 and 4). This figure was 
originally published in (9). 
 
Partial proteolysis 
 
Partial proteolysis can be used to probe protein structure 
because proteases recognize and cleave proteins at 
specific motifs. For example, trypsin cleaves proteins at 
arginine or lysine residues. The rate of cleavage can be 
influenced by sequence context and fold of the protein. 
The initial cleavages on a folded protein will be at 
surface-exposed residues, leading to a specific partial 
digestion pattern. If the protein undergoes a 
conformational change it may alter the exposed residues, 
causing a change in the partial proteolytic pattern. 
Therefore, partial proteolysis can be used to test the 
ability of mutations to alter the structure of a protein. As 
another measure of effects from our mutants, we 
assessed their partial proteolysis pattern with papain. 
Figure 5 illustrates a mutant P with a different protease 
digestion pattern than wild-type P. Different partial 
proteolysis patterns show that the mutations affected the 
structure of the protein, consistent with disrupted 
binding at the putative contact site. 
 
Monoclonal antibodies as inhibitors of protein activity 
 
Mabs can be used to probe protein-protein interactions 
even without differential exposure of their epitopes 
because binding of an antibody at or near a binding site 
can sterically inhibit the interaction. Binding can also 
induce a conformational alteration to the protein and 
hence affect the function of the protein. The effect of 
disruption of the binding site can be measured by 
determining protein function after mAbs are allowed to 
bind their epitopes. Mabs that alter the function of the 
protein must be able to bind their epitopes, whereas 
those that have no effect on the protein may not be able 
to bind. This technique provides epitope exposure 
information and shows direct inhibitory effects of 
binding. Figure 6 shows the effect that various mAbs 
have on protein function in DHBV P. Data such as these 
imply that the epitopes are near important regions and 
may participate in protein function. 
 
 
Fig. 5: Mutations can alter partial proteolysis pattern. P was partially 
digested with papain and the fragments were resolved by SDS-PAGE. 
Lanes 1-4 show wild-type P and lanes 5-8 show P with mutations which 
disrupt the contact site on P. ε is a RNA stem loop required for proper 
folding and activation of P. Note the lack of the protected fragment in the 
digestion of mutant protein (compare lanes 4 and 8). 
 
 
Fig. 6: Monoclonal antibodies can inhibit protein function. In vitro 
translated P was incubated with the indicated monoclonal antibodies and 
a DNA priming assay was performed. Priming signals were normalized to 
activity of P without antibody. NM6 is an irrelevant control antibody. This 
figure was originally published in (9). 
 
Peptide competition 
 
Peptide competition can greatly strengthen identification 
of a protein motif as a binding site. A peptide containing 
the binding motif can bind its ligand, competitively 
displacing the normal protein ligand leading to a dose-    
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dependent decrease in protein activity. This experiment 
is useful because the previous techniques only imply a 
binding interaction. For example, the differential epitope 
exposure could be due to a change in a conformationally 
dependent epitope. However, successful displacement of 
a ligand through peptide competition directly indicates 
binding. An example of this type of dose-dependent 
displacement is seen with imidazole competing for 
binding to Ni+ columns in histidine tag protein 
purification. Demonstrating specificity through the use 
of negative control peptides is essential in this assay. An 
ideal negative control peptide would contain the 
putative binding site with mutations known to prevent 
binding. If this is not possible due to solubility issues that 
can occur with synthetic peptides, a peptide containing 
the same amino acids whose order has been scrambled is 
also an excellent control to demonstrate specificity for 
the putative ligand. Figure 7 is an example of peptide 
competition using a peptide containing the binding site 
and an irrelevant peptide. Another interpretation of our 
results is that the peptide exerts its inhibition by 
inhibiting folding or binding to a chaperone partner. We 
have excluded this possibility by showing that a purified 
active truncation of P, which does not require 
interactions with any chaperones, is inhibited by the T3 
peptide (data not shown). 
 
 
Fig. 7: Soluble peptides containing the putative binding site can 
competitively inhibit protein function. P was translated in vitro in the 
presence of the T3 peptide or irrelevant MBP peptide. Priming was 
initiated by addition of MgCl2 and [α-32P]dGTP. Priming signal was 
normalized to the activity of P without DMSO or peptide. Peptide 
concentration is in mM and error bars are the standard deviation from 4 
experiments. This figure was originally published in (9). 
 
DISCUSSION 
 
Many techniques such as GST-pulldown exist to identify 
protein-protein interactions, but intra-molecular protein 
contacts and contacts dependent on the native fold of a 
protein or formation of a macromolecular complex are 
difficult if not impossible to analyze by these common 
techniques. For example, many current techniques detect 
interactions between protein fragments, which can lead 
to artifactual positive or false negative results if the 
fragments do not fold properly. Therefore, there is a need 
for alternate techniques to address putative protein-
protein interactions. The approach presented here differs 
from more common techniques as it combines 
assessment of physical interaction with functional assays 
using intact proteins under physiological conditions. The 
strength of the technique is that binding is assessed 
within unmodified functional proteins or protein 
complexes. The weakness of this approach is that it 
cannot formally exclude alternate interpretations of the 
data such as a role for the identified sites in essential 
local protein structure. Therefore, whenever possible 
these approaches should be complimented by data from 
crosslinking, surface plasmon resonance or similar 
techniques that measure binding directly.  
 
Protein contact sites are important because they are 
involved in almost every biological process and are 
therefore fundamental to cellular function. Furthermore, 
understanding these contacts provides insight into 
protein structure, and the contacts themselves can be 
promising drug targets. Both cellular and viral protein 
contacts have been targeted for disruption. Small 
molecules targeting tubulin polymerization (17) and BCL 
proteins involved in apoptotic signaling [reviewed in 
(18)] have shown promise as anti-cancer agents. Peptides 
have been effective in blocking the interaction between 
the SARS coronavirus and cellular protein angiotensin-
converting enzyme 2, the first step in viral infection (19). 
In DNA viruses, contact sites have been disrupted using 
both peptides and small molecules, leading to ablation of 
virus replication. The first example of this was a 
nonapeptide used to block subunit interaction in the 
herpes simplex virus ribonucleotide reductase (20). More 
recently researchers have used peptides to block 
interactions between subunits of several DNA 
polymerases [reviewed in (21, 22)]. This strategy has 
been successfully demonstrated with viruses such as     
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herpes simplex virus (23), human cytomegalovirus (24) 
and Rous sarcoma virus (25). In addition, peptides have 
been shown to block interactions in the reverse 
transcriptase (26), integrase (27) and protease (28) 
proteins of human immunodeficiency virus. All of these 
interactions are potential targets for disruption by small 
molecule inhibitors that could serve as drugs. 
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PROTOCOLS
 
Protocol 1: Differential immunoprecipitation 
 
1.  Prepare solid phase: Suspend 20 ul of protein A/G suspension per sample in 1 ml RIPA or IPP150 buffer. Pellet 
agarose, aspirate medium and replace with 300 ul buffer containing 0.1 ug/ul bovine serum albumin. 
2.  Bind antibody to solid phase: Add antibody to the protein A/G agarose suspension. The amount needs to be 
determined for each antibody used. Often 1-5 ul of a polyclonal antibody or 1-50 ul of a monoclonal antibody is 
sufficient. Rock at 4° for 1-2 hours. Wash beads twice with 1 ml cold buffer and suspend protein A/G agarose in 50 
ul RIPA or IPP150 buffer per sample to be immunoprecipitated. 
3.  B i n d  a n t i b o d y  t o  t a r g e t  p r o t e i n :  A d d  1 0  u l  o f  p r o t e i n  t o  1 9 0  u l  o f  R I P A  o r  I P P 1 5 0  b u f f e r .  A d d  5 0  u l  o f  t h e  
appropriate antibody/protein A/G agarose. Rock at 4° for 1.5 hours to overnight.  
4.  Wash immunocomplexes: Centrifuge for 30 seconds in a microcentrifuge. Aspirate the supernatant and add 1 ml 
cold RIPA or IPP150 buffer and vortex for 30 seconds. Repeat 3 times. Centrifuge samples for 1 minute and 
remove all remaining liquid, keeping the pellet intact. 
5.  Prepare samples for electrophoresis: Add 25 ul of Laemmli sample buffer to the pellet. Vortex to resuspend the 
pellet and boil for 4 minutes. Cool the sample on ice and centrifuge 2 minutes. Transfer liquid to new tube, leaving 
the pellet behind.  
6.  Electrophoresis: Resolve 5-20 ul of the sample on an appropriate percentage polyacrylamide gel. 
7.  Analysis of sample: Detect protein by autoradiography (if radioactive) or Western blot. Be sure to include a 
sample of un-immunoprecipitated protein as an immunoprecipitation yield control. 
 
Solutions needed 
 
IPP150 - 10 mM Tris pH 7.5, 150 mM NaCl, 0.1% NP40 
 
RIPA - 20 mM Tris pH 7.2, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate 
 
Laemmli protein sample buffer (5X) - 10% sodium dodecyl sulfate, 20% glycerol, 125mM Tris pH 6.8, 0.1% 
Bromophenol blue, 10% 2-mercaptoethanol 
 
Protocol 2: Partial protease digestion 
 
1.  Prepare protein. 
2.  Dilute protease into ice-cold water. Exact dilution needs to be determined for each stock of enzyme. 
3.  Transfer 5 ul of protein to a fresh pre-chilled tube on ice. 
4.  Add 5 ul water to one set of tubes and place on ice (mock digestion). 
5.  Add 5 ul diluted protease to other set of tubes, making sure they stay ice cold. 
6.  Place all tubes at 14° for 10 minutes. Rapidly terminate digestion by placing entire set of tubes directly into ice 
water when digestion is finished. Adjust time, temperature, concentration of protease, and type of protease used 
empirically until reproducible partial proteolysis is achieved. 
7.  Stop the reaction by adding 20 ul 2X Laemmli sample buffer on ice. 
8.  Boil samples for 4 minutes and load 10-15 ul on a polyacrylamide gel. 
9.  Analyze samples as described in Protocol 1. 
 
Solutions needed 
 
Laemmli protein sample buffer (5X) - See Protocol 1. 
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Protocol 3: Peptide competition assay 
 
1.  Dissolve peptides in dimethyl sulfoxide (DMSO), and then dilute with water to a final concentration of 10 mM 
and 10% DMSO.  
2.  Add peptides to the in vitro translation mix: 
•  14 ul rabbit reticulocyte lysate 
•  0.4 ul RNAsin (Promega) 
•  0.4 ul AA mix (minus methionine) 
•  1.2 ul [35S]Methionine 
•  2 ul mRNA+ε (1ug/ul) 
•  2 ul DEPC water, 10% DMSO or peptide 
•  20 ul total volume 
Incubate at 30° for 60 minutes. Stop translation by adding cyclohexamide (final concentration 80 µM). Include 
translation controls. 
3.  Add 2 µl of 1:1 mixture of 48 mM MgCl2:[α-32P]dGTP (10 mCi/ml) to permit DNA priming. 
4.  Stop reaction by adding 30 ul of 2X Laemmli protein sample buffer. 
5.  Boil samples for 4 minutes and load 15 ul on a polyacrylamide gel. 
6.  Fix, dry and expose gels to autoradiography film or phosphorimager with a sheet of exposed film covering the 
priming samples to block 35S signals. 
7.  Quantitate 35S and 32P signals by densitometry or phoshorimage analysis. Normalize signal to P without DMSO or 
peptide. 
 
Solutions needed 
 
Laemmli protein sample buffer (5X) - See Protocol 1.  
 